Small Proportion of Advanced Breast Cancers Due to Biennial Versus Annual Mammogram

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 12, 2023.

By Elana Gotkine HealthDay Reporter

TUESDAY, Dec. 12, 2023 -- Among routinely screened women, only a small proportion of advanced breast cancers is attributed to biennial versus annual screening, according to a study published online Dec. 7 in JAMA Oncology.

Karla Kerlikowske, M.D., from the University of California in San Francisco, and colleagues examined the population attributable risk proportions (PARPs) for advanced-stage breast cancer associated with clinical risk factors among routinely screened women aged 40 to 74 years. A total of 904,615 women underwent 3,331,740 annual or biennial screening mammograms associated with 1,815 advanced breast cancers diagnosed within two years of screening.

The researchers found that body mass index PARPs were larger for postmenopausal versus premenopausal women (30 versus 22 percent) and were highest among postmenopausal Black and Hispanic/Latinx women and premenopausal Black women (38.6, 31.8, and 30.3 percent, respectively), with the highest overall prevalence of overweight/obesity in premenopausal Black women and postmenopausal Black and Hispanic/Latinx women (84.4, 85.1, and 72.4 percent, respectively). Premenopausal versus postmenopausal women had larger breast density PARPs (37 versus 24 percent), which were highest for premenopausal Asian or Pacific Islander and White women (46.6 and 39.8 percent), who had a high prevalence of dense breasts (62 to 79 percent). For family history of breast cancer, history of breast biopsy, and screening interval, PARPs were small for premenopausal and postmenopausal women (5 to 8, 7 to 12, and 2.1 to 2.3 percent, respectively).

"Mammography is not sufficient to exclude advanced breast cancer diagnoses," the authors write. "Primary prevention is also needed and should focus on interventions to assist patients with overweight/obesity to attain normal weight to reduce their risk of poor-prognosis tumors."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2023-12-13 02:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords